top of page

Latest News

Guilford Street Laboratories is proud to announce we’ve been awarded an Arm's-Length Medical Grant from Chiesi Limited to advance our groundbreaking ImmunoTADA platform. This support accelerates our mission to bring precision medicine to the forefront of rare disease care.

Please see full press release below:

GSL linkedin post  (3).png

Guilford Street Laboratories Awarded Arm’s-Length Medical Grant from Chiesi Limited to Advance ImmunoTADA Platform into Clinical Setting

Guilford Street Laboratories, a leading innovator in translational immunology and advanced bioanalytical technologies, today announced it has been awarded a medical grant from Chiesi Limited. This grant will support the clinical implementation of the company’s proprietary Immuno-Targeted Anti-Drug Antibody (TADA) platform, the world’s first mass spectrometry-based system designed to quantify, subclass, and isotype the antibody response to both enzyme replacement therapies (ERT) and adeno-associated virus (AAV) gene therapy vectors.

The ImmunoTADA platform provides an innovative, alternative approach to immunoassays and addresses a critical need in precision medicine by providing clinicians and researchers with comprehensive immune response profiling at a level that is not available through any other platform. ImmunoTADA is a translational success story and was conceived and developed by GSLs academic founders Prof Kevin Mills and Dr Wendy Heywood with support from the Great Ormond Street Biomedical Research Centre and UCL Translational Research Office. By translating this cutting-edge technology into a clinical setting, Guilford Street Laboratories will empower physicians with actionable insights that can guide patient-specific therapeutic strategies, improve safety and efficacy outcomes, and ultimately enhance patient care in rare disease management.  In addition, the test has been developed for rapid analyses and fast turnaround times to give clinicians immediate data to make informed decisions on a patient’s treatment regime.

“The ImmunoTADA platform represents a paradigm shift in how we monitor and understand immune responses to advanced therapies,” said Dr Tomas Baldwin, CEO of Guilford Street Laboratories. “With the grant support here from Chiesi Limited, we will accelerate the integration of ImmunoTADA into the clinical environment, helping clinicians and patients alike benefit from more tailored, data-driven treatment decisions.”

The awarded grant will fund key steps in the clinical translation process, including assay validation in a regulated setting, integration of automated workflows, and the development of user-friendly digital reporting tools. As the platform becomes available to healthcare providers, it will enable more precise monitoring of patient responses, inform immunomodulation strategies, and help reduce the risk of treatment-limiting immune complications.

With ImmunoTADA poised to enter the clinical arena, Guilford Street Laboratories is eager to engage with healthcare institutions, clinical laboratories, and key opinion leaders. Together, they will shape a future in which personalised treatment protocols optimise patient outcomes in rare and complex therapeutic landscapes.

bottom of page